Recent

% | $
Quotes you view appear here for quick access.

MediWound Ltd. Message Board

  • exit161gsp exit161gsp Mar 20, 2014 3:54 PM Flag

    Nice finish into the close

    All positive posts so far. Who will be the first to bash this stock?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • spiker53@sbcglobal.net spiker53 Mar 20, 2014 4:32 PM Flag

      From Mediwound Ltd. form F-1
      Our management estimates that the majority of the net proceeds from this offering allocated to the expansion of our sales and marketing infrastructure will be spent on the ongoing expansion of NexoBrid, starting in Europe. Additionally, our management estimates that the majority of the net proceeds from this offering allocated to research and development will be spent on the ongoing development of NexoBrid, both in the Phase III trial in the United States and the pediatric trial in the European Union. The balance of such research and development funding is expected to be allocated to the continued development of EscharEx for debridement of chronic and other hard-to-heal wounds and of our proteolytic enzyme technology for the treatment of connective tissue disorders. Although the costs associated with such research and development plans are uncertain, see "Risk Factors—Clinical drug development is a lengthy and expensive process, with an uncertain outcome," our management currently believes that the use of approximately $25-$30 million on research and development will be sufficient to fund our Phase III trial for NexoBrid in the United States and our pediatric trial in the European Union until completion.

      Sentiment: Buy

 
MDWD
8.26+0.17(+2.10%)Sep 26 4:00 PMEDT